Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract reviews the role of the human KRT 16 wild-type allele in skin and hair development and its association with certain genetic skin disorders, without presenting new findings.

This article discusses a novel mutation in the FERMT1 gene identified in a Spanish family with Kindler’s syndrome but reports no new clinical results.

In this study, targeted inactivation of the integrin-linked kinase gene in melanoblasts led to defects in cell migration, proliferation, and ability to populate the skin, implicating an integrin-linked kinase-Rac1 connection in melanocyte function.

In this study, researchers developed de novo designed hetero-bifunctional proteins as an alternative approach for targeted protein degradation, successfully targeting BCL-xL for degradation in cells and inducing apoptosis, which may expand the range of addressable E3 ligases and disease targets.

This case report describes a unique instance of late-onset Björnstad syndrome in an 18-year-old female, mimicking androgenetic alopecia, and indicates potential improvement with JAK inhibitor baricitinib, highlighting the need for considering this syndrome in similar cases of patterned hair loss in young individuals.

This Patent Highlight discusses recent progress in developing TYK2 inhibitors, which show potential for treating conditions like cancer, alopecia areata, and psoriatic arthritis.

This study demonstrated that skin organoids derived from human stem cells can model cutaneous tuberculosis, revealing that fibrosis development in Mycobacterium tuberculosis-infected organoids is linked to the PI3K-AKT and AP1 pathways in fibroblasts, and suggesting the potential for antifibrotic treatment evaluation.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

The Trichodysplasia spinulosa virus protein can cause abnormal hair growth in mice.

The FDA approved a new Pfizer drug for hair loss in teens.

In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.

This review discusses the various therapeutic uses of Botulinum Toxin Type A and reports high levels of patient satisfaction with minimal adverse effects across several conditions, emphasizing its potential therapeutic importance.

This study found that loss of Ptch1 function in mouse skin's basal cells is sufficient to rapidly induce tumors resembling human basal cell carcinoma, suggesting Ptch1 as a key tumor suppressor.

In this study using C3H/HeJ mice, a single subcutaneous injection of the fusion protein PTH-CBD increased anagen hair follicle counts and promoted hair regrowth comparably to daily oral ruxolitinib, potentially by enhancing beta-catenin production and stimulating anagen transition.

This study identified that dominant mutations in the KLHL24 gene cause epidermolysis bullosa through dysregulated autoubiquitination, leading to excessive degradation of keratin 14.

In this study, the authors concluded that the TS-associated polyomavirus may disrupt Wnt/β-catenin signaling, likely contributing to abnormal hair follicle formation in trichodysplasia spinulosa.

This study found that the restoration of CD103⁺γδ T cells in humans is associated with sustained remission in inflammatory bowel disease, suggesting a conserved role for these cells in limiting disease progression.

This study found that mrp/plf-mRNA expression in murine skin increases in response to different tumor promoters, suggesting its potential as a short-term biomarker for chemical carcinogenesis.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

This study found that TLR2 expression in hair follicle stem cells is crucial for hair follicle maintenance and regeneration, with TLR2-dependent activation potentially offering new therapeutic approaches for hair loss prevention through mechanisms involving immune pathways and CEP administration.

This study reported that a modified version of Thymosin beta 4, called PEG-rTβ4, demonstrated potential as a treatment for acute myocardial infarction by improving cardiac function and reducing cell death via specific biochemical pathways, suggesting its promise in drug development efforts.

This article reviews the genetic and phenotypic characteristics of Trichothiodystrophy and discusses the associated DNA repair defects, but does not report new clinical findings.

This review discusses the composition, activation, and regulation of the JAK/STAT pathway and highlights its role and inhibitors in various diseases, but reports no new experimental results.

This study suggests that erlotinib exacerbates inflammation in a mouse model of skin disease and that IL-1 inhibition could mitigate skin-related side effects of EGFR inhibitors.

This review summarizes the roles of bone morphogenetic proteins in the development and regulation of normal and diseased skin, but it does not provide new clinical results.

Lasheras-Pérez et al. reported that JAK3 and TYK2 proteins are activated in certain forms of primary cicatricial alopecia, suggesting the JAK/TYK/STAT pathway as a potential therapeutic target for these conditions.

This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.